People · Operator
Named in public records as an officer, director or promoter · active 2016–2019 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Palisade Bio, Inc. | — | Biotechnology | Series B | $57.3M | $30.5M | 2016 |
| Landec Corp \Ca\ | — | Other | Series B | $19.4M | $321.7M | 2018 |
| BioEclipse Therapeutics, Inc. | — | Biotechnology | Series A | $10.1M | $366.1M | 2019 |
Catherine Sohn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Catherine Sohn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Hall | 1 | 7 |
| Kenneth Carter | 1 | 6 |
| Elona Baum | 1 | 5 |
| Biao He | 1 | 5 |
| Donald Williams | 1 | 4 |
| Stephen Thau | 1 | 4 |
| Scott Ogilvie | 1 | 4 |
| Andrew Powell | 1 | 3 |
| Steven Goldby | 1 | 3 |
| Mark Frohlich | 1 | 3 |
| David Mazzo | 1 | 3 |
| Robert Tobin | 1 | 3 |
| Richard Daly | 1 | 3 |
| Catherine A. Sohn | 1 | 2 |
| I. Richard Garr | 1 | 2 |
| Mitchell Jones | 1 | 2 |
| Sandford D. Smith | 1 | 2 |
| Cristina Csimma | 1 | 2 |
| Mary Ann Gray | 1 | 2 |
| Stanley Westreich | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.